EP
AMLX icon

Essential Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Essential Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269 Hold
15
– – ﹤0.01% 2589
2026
Q1 		$209 Sell
15
-2
-12% -$28 ﹤0.01% 2600
2025
Q4 		$205 Buy
17
+1
+6% +$14 ﹤0.01% 2427
2025
Q3 		$217 Buy
+16
New +$151 ﹤0.01% 2388

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Essential Partners's AMLX Position: Q2 2026 in Review

Essential Partners held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 15 shares worth $269. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Essential Partners first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Essential Partners held 15 shares of Amylyx Pharmaceuticals worth $269 as of Q2 2026.
  • Essential Partners left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2589 holding.
  • Essential Partners first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.